If at first you don’t succeed in gene therapy, then try, try again. | If at first you don’t succeed in gene therapy, then try ...

China's investigator-initiated trials, once praised for their speediness, have been drawn into scrutiny for a lack of ...

Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy pill, Novo ...

After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now ...

For patients living with Type 2 diabetes in the United Kingdom, a more convenient treatment option may be on the horizon ...

Less than a year after the FDA turned down the resubmitted application for the company’s leukemia prospect Dasynoc, Xspray ...

The pharmaceutical industry creates some of the most valuable products in human history: Medicines that can extend, save and better our lives. | The pharmaceutical industry creates some of the most ...

Eight months after more than doubling down on its construction of a $2 billion drug manufacturing facility in Holly Springs, ...

B. Braun Medical—a maker of IV solutions for hospitals, among other products—has initiated a recall in the United States and ...

Boehringer Ingelheim has continued its rise up patient groups’ ranking of rare disease companies, adding to last year’s gains to cement its status toward the top of the leaderboards. | Boehringer ...

Aurinia Pharmaceuticals has struck a patent infringement settlement with Teva Pharmaceuticals, which should help stave off ...